针对性的CDK9降解会严重破坏MYC监管的网络
Mohammed A Toure1, Keisuke Motoyama2, Yichen Xiang1
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; MIT Center for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 04142, USA.
针对性降解循环素依赖性激酶9 (CDK9) 比抑制更有效,用于癌症治疗. 降解克服了反机制,限制了CDK9抑制剂的有效性,特别是在MYC调节方面.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 循环素依赖性激酶9 (CDK9) 对于转录至关重要,并与癌症有关.
- 现有的CDK9抑制剂在临床上取得了有限的成功.
- 向蛋白质降解是一种新兴的治疗策略.
研究的目的:
- 为了比较CDK9降解与抑制的治疗潜力.
- 评估对MYC转录调节和核细胞平衡的影响.
- 确定克服当前CDK9向疗法的局限性的策略.
主要方法:
- 开发一种选择性和强大的CDK9降解剂.
- 对CDK9降解和抑制的下游影响进行比较.
- 对MYC表达和核细胞平衡的分析.
- 研究CDK9的酶和支架功能.
主要成果:
- CDK9抑制触发了补偿反循环,减少了对MYC的影响.
- CDK9降解有效地破坏了MYC的转录调节.
- 降解导致核细胞平衡的不稳定.
- 补偿反机制在CDK9降解时不存在.
结论:
- 与抑制相比,CDK9降解提供了一种优越的策略.
- 降解克服了限制抑制剂有效性的反机制.
- 有针对性的CDK9降解显示出克服瘤学治疗挑战的前景.
更多相关视频
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers
Published on: September 26, 2019
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
相关概念视频
Positive Regulator Molecules
Positive Regulator Molecules
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex
Inhibition of CDK Activity
